The detection and significance of minimal residual disease in acute and chronic leukemia

被引：19

作者：

Chung, N. -G. ^{[1
]}

Buxhofer-Ausch, V. ^{[1
]}

Radich, J. P. ^{[1
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Program Genet & Genom, Div Clin Res, Seattle, WA 98109 USA

来源：

TISSUE ANTIGENS | 2006年 / 68卷 / 05期

关键词：

leukemia; minimal residual disease; relapse;

D O I：

10.1111/j.1399-0039.2006.00714.x

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Minimal residual disease (MRD) can be detected in many patients with leukemia who have achieved complete remission as defined by conventional pathology examination. The detection of MRD, be it by flow cytometry or by polymerase chain reaction assays, has now been found to be associated with subsequent relapses in most leukemia subtypes, either following chemotherapy or following hematopoietic stem cell transplantation. These assays are now increasingly used in clinical trial design to optimize therapy and provide a novel way to assess treatment efficacy.

引用

页码：371 / 385

页数：15

共 141 条

[1]

ARTHUR CK, 1988, BLOOD, V71, P1179

[2] Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL [J].

Bader, P ;

Hancock, J ;

Kreyenberg, H ;

Goulden, NJ ;

Niethammer, D ;

Oakhill, A ;

Steward, CG ;

Handgretinger, R ;

Beck, JF ;

Klingebiel, T .

LEUKEMIA, 2002, 16 (09) :1668-1672

[3] Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia [J].

Beretta, C ;

Gaipa, G ;

Rossi, V ;

Bernasconi, S ;

Spinelli, O ;

Dell'Oro, MG ;

Rizzari, C ;

Rambaldi, A ;

Biondi, A ;

Cazzaniga, G .

LEUKEMIA, 2004, 18 (08) :1441-1444

[4] Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapse in acute leukaemia [J].

Bernell, P ;

Arvidsson, I ;

Jacobsson, B ;

Hast, R .

BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (04) :666-672

[5] Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia [J].

Björklund, E ;

Mazur, J ;

Söderhäll, S ;

Porwit-MacDonald, A .

LEUKEMIA, 2003, 17 (01) :138-148

[6] Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state [J].

Bounamici, S ;

Ottaviani, E ;

Testoni, N ;

Montefusco, V ;

Visani, G ;

Bonifazi, F ;

Amabile, M ;

Terragna, C ;

Ruggeri, D ;

Piccaluga, PP ;

Isidori, A ;

Malagola, M ;

Baccarani, M ;

Tura, S ;

Martinelli, G .

BLOOD, 2002, 99 (02) :443-449

[7] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[8] Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase [J].

Branford, S ;

Rudzki, Z ;

Harper, A ;

Grigg, A ;

Taylor, K ;

Durrant, S ;

Arthur, C ;

Browett, P ;

Schwarer, AP ;

Ma, D ;

Seymour, JF ;

Bradstock, K ;

Joske, D ;

Lynch, K ;

Gathmann, I ;

Hughes, TP .

LEUKEMIA, 2003, 17 (12) :2401-2409

[9]

Branford S, 1999, BRIT J HAEMATOL, V107, P587

[10] Molecular relapse can be detected in blood in a sensitive and timely fashion in B-lineage acute lymphoblastic leukemia [J].

Brisco, MJ ;

Sykes, PJ ;

Hughes, E ;

Story, CJ ;

Rice, MS ;

Schwarer, AP ;

Morley, AA .

LEUKEMIA, 2001, 15 (11) :1801-1802

← 1 2 3 4 5 6 7 8 9 10 →